Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 2, 2014, Pages

  Portal, Alix ^a   Pernot, Simon ^a   Siauve, Nathalie ^a   Landi, Bruno ^a   Lepère, Céline ^a   Colussi, Orianne ^a   Rougier, Philippe ^a   Zaanan, Aziz ^a   Verrière, Benjamin ^a   Taieb, Julien ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; FOLFIRINOX; GEMCITABINE; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; EPIGASTRIC PAIN; HUMAN; LIVER BIOPSY; LIVER METASTASIS; MEDICAL HISTORY; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; REMISSION; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, PANCREATIC DUCTAL; MALE; PALLIATIVE THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT FAILURE;

ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CAMPTOTHECIN; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PALLIATIVE CARE; PANCREATIC NEOPLASMS; TREATMENT FAILURE;

EID: 84899485802     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.01.005     Document Type: Article

References (12)

1. Parkin D., Bray F., Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37:4-66.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29.
3. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
4. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
5. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 16. [epub ahead of print].
6. Neuzillet C., Tijeras-Raballand A., Cros J., Faivre S., Hammel P., Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013, 21. [epub ahead of print].
7. Rahma O., Duffy A., Liewehr D., Steinberg G., Greten T. Second line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013, 24:1972-1979.
8. Pelzer U., Schwaner I., Stieler J., Adler M., Seraphin J., Dörken B., et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011, 47:1676-1681.
9. Dahan L., Bonnetain F., Ychou M., Mitry E., Gasmi M., Raoul J.L., et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59:1527-1534.
10. Hosein P., de Lima Lopes G., Pastorini V., Gomez C., Macintyre J., Zayas G., et al. A phase II trial of Nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013, 36:151-156.
11. Scripture C., Figg W., Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 2006, 4:165-172.
12. Trouilloud I., Dupont-Gossard A.C., Artru P., Lecomte T., Gautier M., Aparicio T., et al. FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): results of the randomized multicenter AGEO phase II trail FIRGEM. J Clin Oncol 2012, 30(Suppl. abstr 4018).